Oak Thistle LLC Purchases 648 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Oak Thistle LLC lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report) by 51.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,913 shares of the medical research company’s stock after buying an additional 648 shares during the quarter. Oak Thistle LLC’s holdings in Bio-Rad Laboratories were worth $618,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Atlas Capital Advisors LLC bought a new position in shares of Bio-Rad Laboratories in the second quarter valued at $50,000. Farther Finance Advisors LLC boosted its position in Bio-Rad Laboratories by 42.3% during the second quarter. Farther Finance Advisors LLC now owns 101 shares of the medical research company’s stock worth $38,000 after purchasing an additional 30 shares during the period. Pacific Center for Financial Services bought a new position in Bio-Rad Laboratories during the first quarter worth $49,000. ING Groep NV bought a new position in Bio-Rad Laboratories during the third quarter worth $44,000. Finally, Dark Forest Capital Management LP boosted its position in Bio-Rad Laboratories by 1,160.0% during the first quarter. Dark Forest Capital Management LP now owns 126 shares of the medical research company’s stock worth $60,000 after purchasing an additional 116 shares during the period. 65.24% of the stock is owned by institutional investors.

Bio-Rad Laboratories Trading Down 0.2 %

Shares of Bio-Rad Laboratories stock opened at $328.19 on Thursday. The firm has a 50-day moving average of $333.80 and a 200-day moving average of $324.03. The stock has a market cap of $9.36 billion, a PE ratio of -15.27 and a beta of 0.87. Bio-Rad Laboratories, Inc. has a 52-week low of $261.59 and a 52-week high of $494.05. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83.

Bio-Rad Laboratories (NYSE:BIOGet Free Report) last announced its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.17. The company had revenue of $681.18 million during the quarter, compared to analysts’ expectations of $685.00 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. Bio-Rad Laboratories’s quarterly revenue was down 6.7% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.31 earnings per share. As a group, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on BIO shares. StockNews.com raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, March 15th. Royal Bank of Canada reduced their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $400.00 to $365.00 in a research report on Wednesday. Finally, UBS Group lifted their price objective on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $468.00.

View Our Latest Stock Report on BIO

Insider Activity at Bio-Rad Laboratories

In related news, EVP Michael Crowley sold 3,000 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $336.00, for a total value of $1,008,000.00. Following the completion of the transaction, the executive vice president now owns 6,942 shares of the company’s stock, valued at $2,332,512. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 17.06% of the stock is owned by insiders.

Bio-Rad Laboratories Company Profile

(Free Report)

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.

Read More

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOFree Report).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.